Telerehabilitation Protocols With Digital and Robotic Tools for People
Development and Implementation of Telerehabilitation Protocols With Digital and Robotic Tools for the Continuity of Care of People With Chronic Neurological Disorders - TELENEURO@REHAB"
We could not find results for this trial
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- medical device "Homing" (TecnoBody); medical device "Icone" (Heaxel)
Compared with
- Usual Care
What it measured
Main measures
Change in the perceived level of disability as measured by the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0, Federici et al., 2017)
Baseline, post-treatment, and follow-up (2 months after the end of treatment)
Thinking and memoryWalking and mobility
Other measures (14)
Change in global cognitive functioning as measured by the Montreal Cognitive Assessment (MoCA test, Conti et al., 2015) in PD, MS, and post-stroke groups
Baseline, post-treatment, and follow-up (2 months after the end of treatment)
Thinking and memoryChange in visuoperceptual and attentional abilities as measured by the Trail Making Test (TMT part A and B, Giovagnoli et al., 1996) in PD, MS, and post-stroke groups
Baseline, post-treatment, and follow-up (2 months after the end of treatment)
Thinking and memoryChange in visuoperceptual and attentional abilities as measured by the and the Symbol Digit Modalities Test (SDMT; Smith A., 1973; Nocentini U., 2006) in PD, MS, and post-stroke groups
Baseline, post-treatment, and follow-up (2 months after the end of treatment)
Thinking and memoryChange in depressive symptoms as measured by the Beck Depression Inventory for Primary Care (BDI-PC, Steer et al., 1999) in PD, MS, and post-stroke groups
Baseline, post-treatment, and follow-up (2 months after the end of treatment)
Mood and sleepChange in anxiety level as measured by the State-Trait Anxiety Inventory - Form Y (STAI - Y2; Spielberger, 1983; Pedrabissi & Santinello, 1989) in PD, MS, and post-stroke groups
Baseline, post-treatment, and follow-up (2 months after the end of treatment)
Mood and sleepChange in gross manual dexterity as measured by the Box and Block Test (BBT; Desrosiers et al., 1994) in PD, MS, and post-stroke groups
Baseline, post-treatment, and follow-up (2 months after the end of treatment)
Arm and hand functionChange in finger dexterity as measured by the Nine Hole Peg Test (Feys et al., 2017) in PD and MS groups
Baseline, post-treatment, and follow-up (2 months after the end of treatment)
Arm and hand functionChange in dynamic balance as measured by the modified Dynamic Gait Index (mDGI; Anastasi et al., 2019) in PD and MS groups
Baseline, post-treatment, and follow-up (2 months after the end of treatment)
Walking and mobilityChange in static and dynamic balance as measured by the Mini-Best Test (Franchignoni et al., 2010) in PD and MS groups
Baseline, post-treatment, and follow-up (2 months after the end of treatment)
Walking and mobilityChange in perceived stability during activities of daily living as measured by the Activities Balance Confidence scale (ABC; Cattaneo et al., 2006; Franchignoni et al., 2014) in PD and MS groups
Baseline, post-treatment, and follow-up (2 months after the end of treatment)
Walking and mobility
Who could take part
MS (type not specified) · 25 to 85
Show the full criteria
Inclusion criteria
1. diagnosis of chronic post-stroke condition with ischemic or haemorrhagic stroke injury occurred 4-6months before recruitment and with motor impairment of the upper limb > 2 to the Medical Research Council scale (MRC); or diagnosis of probable PD according to MDS criteria (Postuma et al., 2015) in staging between 1.5 and 3 on the Hoehn \& Yahr scale (Goetz et al., 2004); or diagnosis of MS, RR-SP forms, according to the criteria of MC Donald 2010 (Polman et al., 2011) with disability level at the Expanded Disability Status Scale EDSS (Kurtzke, 1983) \< 6; 2. age between 25 and 85 years; 3. preserved cognitive level at the Montreal Cognitive Assessment test (MoCA test >17.36) (Conti et al., 2015); 4. agreement to participate with the signature of the informed consent form; 5. no rehabilitation program in place at the time of enrolment; 6. stable drug treatment (last 3 months) with L-Dopa or dopamine agonists (PD group) and/or cortisone (MS group).
Exclusion criteria
1. presence of comorbidities that might prevent patients from undertaking a safe home program or determining clinical instability (i.e., severe orthopedic or severe cognitive deficits); 2. presence of major psychiatric complications or personality disorders; 3. presence of severe impairment of visual and/or acoustic perception; 4. relapse ongoing/at least 3 months since the last relapse (MS group); 5. presence of "frequent" freezing as recorded at the administration of Section II (daily life activity) of the UPDRS (score ≥ 3) (PD group); 6. falls resulting in injuries or a number of falls ≤ 2 in the 6 months prior to recruitment (PD and MS groups).
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The goal of this clinical trial is to test an innovative telerehabilitation protocol in people with Chronic Neurological Disorders (Parkinson's disease, Multiple Sclerosis, and post-stroke). The main questions it aims to answer are 1)the usability and acceptability of the system; 2)the level of safety of intervention; 3) the efficacy of the telerehabilitation protocol. Participants will be randomized (with an allocation ratio of 1:1) into either the experimental group (20 sessions of motor telerehabilitation with digital and robotic tools) or the active control group (20 motor rehabilitation sessions performed at home according to the usual care treatment procedure). Researchers will compare the experimental group and the active control group to see if the TR protocol with digital and robotic tools is effective in reducing the perceived level of disability.
Papers
Loading reviews and guidelines…
History
Started
Sept 2023
Main results due
May 2024
Finished
Jan 2025